Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders.
G-protein-coupled receptor (GPCR)-mediated signalling is the most widely used signalling mechanism in cells, and its regulation is important for various physiological functions. The cannabinoid-1 (CB(1)) receptor, a GPCR, has been shown to play a critical role in neural circuitries mediating motivation, mood and emotional behaviours. Several recent studies have indicated that impairment of CB(1) receptor-mediated signalling may play a critical role in the pathophysiology of various neuropsychiatric disorders. In this article, the authors briefly review literature relating to the role played by the endocannabinoid system in various neuropsychiatric disorders, and the CB(1) receptor as a potential therapeutic target for the treatment of alcoholism, depression, anxiety and schizophrenia.
New York State Psychiatric Institute, Division of Analytical Psychopharmacology, New York, USA.
K Yaragudri
KY
Vinod
Basalingappa L
BL
Hungund
D063385:Cannabinoid Receptor Modulators / Q000008:administration & dosage / Q000378:metabolism; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000378:metabolism* / Q000523:psychology; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism*
D063385:Cannabinoid Receptor Modulators; D043884:Receptor, Cannabinoid, CB1